These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30381505)

  • 1. The long-term impact of hepatitis C infection in kidney transplantation in the pre-direct acting antiviral era.
    Radhakrishnan RC; Gopal B; Zachariah UG; Abraham P; Mohapatra A; Valson AT; Alexander S; Jacob S; Tulsidas KS; David VG; Varughese S
    Saudi J Kidney Dis Transpl; 2018; 29(5):1092-1099. PubMed ID: 30381505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver Transplant From Increased-Risk Donors in the Era of Direct-Acting Antivirals for Hepatitis C.
    Shaikh OS; Rogal S; Malik A; Sharma V; Cacciarelli T
    Exp Clin Transplant; 2020 Oct; 18(5):605-611. PubMed ID: 31324136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes in HIV+/HCV+ coinfected kidney transplant recipients in the pre- and post-direct-acting antiviral therapy eras: 10-Year single center experience.
    Camargo JF; Anjan S; Chin-Beckford N; Morris MI; Abbo LM; Simkins J; Ciancio G; Chen LJ; Burke GW; Figueiro J; Guerra G; Kupin WL; Mattiazzi A; Ortigosa-Goggins M; Ram Bhamidimarri K; Roth D
    Clin Transplant; 2019 May; 33(5):e13532. PubMed ID: 30866102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct-acting antiviral drugs against hepatitis C virus in renal transplant recipients: Is it the dawn of an interferon-free Era?
    Rangaswamy D; Nagaraju SP; Attur RP
    Saudi J Kidney Dis Transpl; 2017; 28(5):1169-1174. PubMed ID: 28937081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant.
    Yoshida EM; Kwo P; Agarwal K; Duvoux C; Durand F; Peck-Radosavljevic M; Lilly L; Willems B; Vargas H; Kumar P; Brown RS; Horsmans Y; De-Oertel S; Arterburn S; Dvory-Sobol H; Brainard DM; McHutchison JG; Terrault N; Rizzetto M; Müllhaupt B
    Ann Hepatol; 2017; 16(3):375-381. PubMed ID: 28425407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Sofosbuvir and Ribavirin for Eradicating Hepatitis C Virus in Renal Transplant Recipients in Pakistan: Where Resources Are Scarce.
    Hanif FM; Laeeq SM; Mandhwani RK; Luck NH; Aziz T; Mehdi SH
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):63-67. PubMed ID: 28260436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection.
    Yoshida EM; Lilly LB; Marotta PJ; Mason AL; Bilodeau M; Vaillancourt M
    Ann Hepatol; 2013; 12(2):282-93. PubMed ID: 23396740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct-Acting Antiretroviral Therapy in Renal Transplant Recipients With Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Report of Our Experience and Literature Review.
    Moreno-Ramirez M; Villanego F; Vigara LA; Cazorla JM; Naranjo J; Garcia T; Merino MJ; Mazuecos A
    Transplant Proc; 2020 Mar; 52(2):523-526. PubMed ID: 32035678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C Virus NAT-Positive Solid Organ Allografts Transplanted Into Hepatitis C Virus-Negative Recipients: A Real-World Experience.
    Kapila N; Menon KVN; Al-Khalloufi K; Vanatta JM; Murgas C; Reino D; Ebaid S; Shaw JJ; Agrawal N; Rhazouani S; Navas V; Sheffield C; Rahman AU; Castillo M; Lindenmeyer CC; Miller C; Quintini C; Zervos XB
    Hepatology; 2020 Jul; 72(1):32-41. PubMed ID: 31659775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eradication of hepatitis C virus infection in kidney transplant recipients using direct-acting antiviral therapy: Qatar experience.
    Alkadi MM; Abuhelaiqa EA; Elshirbeny MF; Hamdi AF; Fituri OM; Asim M; Alkaabi SR; Derbala MF; Jarman ME; Ashour AM; Nauman A; Al Maslamani YK; Butt AA; Al-Malki HA
    Immun Inflamm Dis; 2021 Mar; 9(1):246-254. PubMed ID: 33264509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis.
    Vukotic R; Conti F; Fagiuoli S; Morelli MC; Pasulo L; Colpani M; Foschi FG; Berardi S; Pianta P; Mangano M; Donato MF; Malinverno F; Monico S; Tamè M; Mazzella G; Belli LS; Viganò R; Carrai P; Burra P; Russo FP; Lenci I; Toniutto P; Merli M; Loiacono L; Iemmolo R; Degli Antoni AM; Romano A; Picciotto A; Rendina M; Andreone P;
    J Viral Hepat; 2017 Oct; 24(10):858-864. PubMed ID: 28370880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of viral hepatitis in solid organ transplantation].
    Mikolašević I; Sladoje-Martinović B; Orlić L; Milić S; Lukenda V; Župan Ž; Štimac D; Rački S
    Acta Med Croatica; 2014 Apr; 68(2):151-9. PubMed ID: 26012153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation.
    Van Wagner LB; Baker T; Ahya SN; Norvell JP; Wang E; Levitsky J
    J Hepatol; 2009 Nov; 51(5):874-80. PubMed ID: 19643508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Sustained Viral Response With Direct-Acting Agents on Glycemic Control and Renal Function in Hepatitis C Liver Transplant Recipients.
    Saab S; Barnard A; Challita Y; Adeniyi A; Aziz A; Choi G; Durazo FA; El-Kabany MM; Han SB; Busuttil RW
    Exp Clin Transplant; 2018 Aug; 16(4):419-424. PubMed ID: 30060729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No evidence of occult hepatitis C or E virus infections in liver-transplant patients with sustained virological response after therapy with direct acting agents.
    Del Bello A; Abravanel F; Alric L; Lavayssiere L; Lhomme S; Bellière J; Izopet J; Kamar N
    Transpl Infect Dis; 2019 Aug; 21(4):e13093. PubMed ID: 30972874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Treatment of Hepatitis C in Kidney Transplant Recipients With Directly Acting Antiviral Agents.
    Lubetzky M; Chun S; Joelson A; Coco M; Kamal L; Ajaimy M; Gaglio P; Akalin E; De Boccardo G
    Transplantation; 2017 Jul; 101(7):1704-1710. PubMed ID: 28009781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation.
    Cimsit B; Assis D; Caldwell C; Arvelakis A; Taddei T; Kulkarni S; Schilsky M; Emre S
    Transplant Proc; 2011 Apr; 43(3):905-8. PubMed ID: 21486625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Sofosbuvir-Based Regimens for the Treatment of Hepatitis C After Liver Transplant on Renal Function: Results of a Canadian National Retrospective Study.
    Faisal N; Bilodeau M; Aljudaibi B; Hirch G; Yoshida EM; Hussaini T; Ghali MP; Congly SE; Ma MM; Lilly LB
    Exp Clin Transplant; 2019 Feb; 17(1):59-63. PubMed ID: 29619910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
    Shah AP; Cameron A; Singh P; Frank AM; Fenkel JM
    Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28060446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of antiviral therapy in the long-term outcome of recurrent hepatitis C virus infection following liver transplantation.
    García-Reyne A; Lumbreras C; Fernández I; Colina F; Abradelo M; Magan P; San-Juan R; Manrique A; López-Medrano F; Fuertes A; Lizasoain M; Moreno E; Aguado JM
    Transpl Infect Dis; 2013 Aug; 15(4):405-15. PubMed ID: 23725370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.